Adenocarcinoma of the prostate is now the second leading cause of male death from malignant disease in the US and in Europe (Foster, 1990; Geller, 1995) . In common with other malignant diseases, metastasized prostate cancer cells are invariably resistant to all currently available therapies (Foster et al, 1992) . This glaring clinical fact has lent fresh impetus to the need for better understanding of mechanisms underlying metastatic behaviour. Progress on this front has been heightened recently by reproducible models of inducing metastases through transfection of fragmented DNA from malignant tumours into non-metastatic cells (Ke et al, 1998) . Identification and characterization of genes involved in the metastatic phenotype of prostate cancer cells through these model systems hold the promise of propelling much needed advancements in therapy.
Whilst the metastatic cascade may involve complicated multiple genetic changes, angiogenesis is an essential common mechanism for the development and the formation of metastasis in solid tumours. This makes anti-angiogenic therapy an attractive and promising treatment for cancer (Battegay, 1995) . Angiogenesis is regulated by a number of both stimulating and inhibiting angiogenic factors. VEGF is one of the most potent factors for stimulating angiogenesis (Stephan and Brock 1996) . Although VEGF has been previously detected in prostate cancer (Jackson et al, 1997; Ferrer et al, 1998; Haggstrom et al, 1998) , these observations were made in tissue specimens. Thus, it is not clear whether the detected VEGF is made by tumour cells themselves or by their adjacent cells. This is important because VEGF has been reported to be produced by tumour-associated cells like endothelial cells, infiltrated T-cells and macrophages, as well as by surrounding stromal cells (Fukumura et al, 1998) . Furthermore, it is not completely understood whether it is the VEGF or other angiogenic factors, such as basic fibroblast growth factor (FGF) and interleukin-8, which have also been detected in some prostate tissues (Deshmukh et al, 1997; Haggstrom et al, 1998) , that are responsible for neovascularization required for the malignant progression of prostate cancer cells. There is no experimental data to show whether the VEGF produced by a human prostate carcinoma cell line (Ferrer et al, 1997 ) is capable to induce angiogenesis.
In order to make a quantitative assessment of differential expression of VEGF between the benign and the malignant prostate epithelial cells, and particularly, to test the angiogenic ability of the VEGF produced by prostate carcinoma cells, we have performed the present study in well-characterized cell culture system. We have first measured the level of VEGF expression in a wide range of different human and rat prostate cell lines with either benign or malignant properties to determine whether the elevated expression of VEGF is associated with the increased malignant characteristics of the cells. Then, we have examined Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells whether the ability of producing high level of VEGF can be transferred as the transformation of the metastatic capability of the cells by comparing the VEGF levels in three metastatic variants with that in their parental benign cells. These metastatic variants have been generated by transfection of a benign cell line with genomic DNA extracted from prostate carcinoma cells (Ke et al, 1998) . Finally, we employed an in vivo angiogenesis assay to determine whether the VEGF produced by the malignant cells can induce new blood vessel formation.
MATERIALS AND METHODS

Cell lines and culture conditions
Three groups of 13 well-characterized benign and malignant cell lines were used in this study. The first group is the four human prostate cell lines which include one benign cell line and three malignant cell lines. The benign cell line PNT-2 was derived from human prostate epithelial cells (Cussenot et al, 1991 (Cussenot et al, , 1994 Berthon et al, 1995) . One of the malignant cell line LNCap was derived from prostate carcinoma (Horoszewicz et al, 1983) , and other two malignant cell lines, PC-3 and DU145, were derived from malignant metastases of prostate cancer in rib and brain respectively (Kaighn et al, 1978; Stone et al, 1978) . The second group of cell lines examined in this study was the five biologically distinct sublines from the Dunning R3327 rat prostate carcinoma model (Isaacs et al, 1986 ). The G cell line is the least malignant cell line and it can induce only less than 5% of animals with metastasis when introduced into the syngeneic rats. The second cell line in this group was the weakly metastatic cell line AT-2, which can induce up to 20% of animals with metastasis. The remaining three cell lines in this group were the highly metastatic cell lines AT-3, MAT-Lu and AT-6.1, which can induce more than 75% of animals with metastasis. The last group of cell lines used in this study was the benign rat cell line Rama 37 (Dunnington et al, 1983) and its three malignant metastatic sublines established by transfecting the Rama 37 cells with DNA extracted from prostate carcinoma cells (Ke et al, 1998) . The human and rat cell lines were grown as monolayer cultures in RPMI-1640 (human cells) and Dulbecco's modified Eagles medium (DMEM) (rat cells) media, supplemented with 10% (v/v) fetal calf serum, hydrocortisone (5 ng ml -1 ), penicillin (100 units ml -1 ) and streptomycin (100 mg ml -1 ), with either testosterone (5 ng ml -1 , for human and rat prostate cells), or insulin (5 ng ml -1 , for Rama 37 and its derivative lines).
cDNA probes
The human VEGF probe used in this study was a 655-bp cDNA fragment (a gift from ZENECA Pharmaceuticals). Both glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and actin probes were purchased from CLONTECH Laboratory (UK). The rat VEGF probe was a 601-bp cDNA fragment prepared by reverse transcription polymerase chain reaction (RT-PCR), using 100 ng mRNA extracted from AT-3 cells as template, and using a pair of rat VEGF specific primers (sense: 5′-AACCATGAACTTTCT-GCTCTC-3′; antisense: 5′-GGTGAGAGGTCTAGTTCCCGA-3′). The sequence of the amplified rat VEGF probe was confirmed by nucleotide sequencing analysis using a DNA sequencing kit (Amersham Life Science). Each probe containing 25 ng cDNA was labelled with [α-32 P]dCTP to a specific radioactivity of 0.5-1.0 × 10 9 dpm µg -1 cDNA using a random promed DNA labelling kit (Boehringer Mannheim GmbH, Germany).
Detection of VEGF mRNA
The expression of VEGF mRNA in different cell lines were detected by Northern blotting. Total RNA was isolated from each cell line by lysing the cells with 4 M guanidine isothiocyanate and purified by CsCl gradient centrifugation. The mRNA was further purified from total cellular RNA using Oligotex mRNA Kit (Qiagen Ltd, UK). Northern blotting was performed as described previously (Alwine et al, 1977) . Briefly, total RNA (10 µg) was separated by electrophoresis in a 0.8% denaturing formaldehyde-agarose gels. The separated RNAs were transferred onto a nylon Hybond-N membrane (Amersham Inc, UK) overnight by capillary elution. After the membranes were pre-hybridized at 42°C for 3-4 h in the solution containing 50% formamide, 5% Denhardt's, 6 × sodium-saline phosphate-EDTA (SSPE), 0.5% sodium dodecyl sulphate (SDS) and 100 µg ml -1 of denatured sonicated salmon sperm DNA, the membranes were hybridized overnight under the same condition with cDNA probes. The probed membranes were subjected to stringent washes and exposed to Kodak XAR-5 films. The intensity of each band appearing on the film was scanned and analysed with Phoretix 1D-advanced vs 3.1 software. The loading artifact was normalized with the constitutively expressed GAPDH or actin mRNAs.
Slot blotting was used for quantitative analysis of VEGF mRNA expressed in four human prostate cell lines. Increasing amounts of mRNA from 0.05 to 1.6 µg were loaded onto a nylon Hybond-N membrane using a slot-blot apparatus (Bio-Rad, Hercule, CA, USA). After fixed by ultraviolet light, the membrane was pre-and hybridized with the radioactively labelled human VEGF probe and GAPDH probe respectively, washed and subjected to autoradiography. Intensities of each band were scanned as described above for Northern blotting. The best-fit straight lines of plots of peak area against the amount of RNA per slot over the linear part of the plot were calculated by linear regression. Any loading artefacts were normalized with the consititutively expressed GAPDH mRNA.
Detection of VEGF protein
In a 96-well microtitre plate, 100 µl of mouse anti-hVEGF monoclonal antibody (1 µg ml -1 in 50 mM of sodium carbonate, pH 9.6) was coated overnight at 4°C. The plate was then blocked with blocking buffer (2% bovine serum albumin (BSA) in phosphatebuttered saline (PBS)) for 2 h at room temperature (RT). Conditioned medium (serum-free medium used for culturing cells for 48 h) or rhVEGF standard (R & D System) was added and incubation continued for another 2 h at RT. Goat anti-hVEGF polyclonal antibody (R & D System) was added (100 µl of 1 µg ml -1 ) to each well after washing the plate with the washing buffer (0.1% Tween-20 in PBS) and then incubated at RT for 2 h. The detection antibody, a peroxidase-labelled rabbit anti-goat IgG (Zymed, USA, 61-1620), was added and reaction continued for another 2 h at RT. The plate was washed again with washing buffer, the substrate solution (0.04% o-phenylenediamine dihydrochloride in PBS plus 0.4 ml l -1 of 30% hydrogen peroxide) was used to develop colour. The colour was quantitated with TiterteK Multiskan PLUS (Flow Laboratories, Finland) at 492 nm. The limit of sensitivity of this assay was 0.4 ng ml -1 .
Analysis of isoforms of VEGF gene transcripts
RT-PCR analysis was performed to study potential splicing variants of the VEGF gene in human cell lines. The first strand of cDNA was synthesized from the poly-adenosine (poly-A) end of the mRNA (100 ng) extracted from both PNT-2 and DU145 cells using the First Strand cDNA Synthesis Kit for RT-PCR (Boehringer). The reverse transcription products (2.5 µl) were amplified by PCR using a primer pair allowing to amplify all possible VEGF isoforms (sense: 5′-TCGGGCCTCCGAAAC-CATGC-3′; antisense: 5′-CCTGGTGAGAGATCTGGTTC-3′). The amplified PCR products were subjected to electrophoresis and visualized by ethidium bromide staining. The products were also transformed onto a nylon membrane (Hybond N, Amersham) and hybridized with the human VEGF probe. To confirm the sequences of products amplified by PCR being VEGF isoforms, the PCR products were cloned into pBlueScript plasmid, and their sequences were determined by nucleotide sequencing analysis using a DNA Sequencing Kit (Amersham Life Science).
Chick chorioallantoic membrane assay
The angiogenic activity of the conditioned media from both the malignant DU145 and the benign PNT-2 cells were determined by the CAM assay, as described previously (West et al, 1985) . Both control medium (serum-free medium without cells) and conditioned medium were concentrated tenfold by centrifugal ultrafiltration (3 kDa cut-off). The rhVEGF 121 protein (positive control) was dissolved in Dulbecco's PBS at a concentration of 100 ng ml -1 . For application to the eggs, a 40 µl aliquot of each sample was mixed with 50 µl of 1% sterile methylcellulose (M-0512, 4000 centipoises, Sigma) and 1 µl PBS or 1 µl anti-hVEGF neutralizing antibody (MAB293, R & D Systems Ltd) at a 50-fold excess concentration to rhVEGF 121. This mixture (10 µl) was then applied on to a 2 mm diameter 'Teflon' column and dried, under sterile conditions, to give a clear disc. The samples were applied on to the CAM on day 10, when vessel growth ostensibly finished. The angiogenic reaction was determined on day 14. The angiogenic reaction was scored as: 0 -negative; 0.5 -change in vessel architecture but not directed to the point of sample application; 1 -partial spokewheel (1/3 of circumference exhibits directional angiogenesis); 2 -spokewheel, 3 or up-strong and fully spokewheel. This approach enabled calculation of accumulated responses for the test samples in each group. For photography, the membranes were fixed in situ with ice-cold 4% paraformaldehyde-PBS that was injected both from above and below the membrane. Membranes were excised, placed on a fresh microscope slide and photographed under a Leitz binocular dissecting microscope and indirect fibreoptic illumination. Statistical analysis was performed using the Mann-Whitney U-test.
RESULTS
VEGF mRNA level in the benign and malignant cell lines
Northern and slot blotting was used to detect the level of VEGF mRNA in human benign and malignant cell lines. The radioactively labelled human VEGF probe detected one VEGF band at a molecular size of about 3.9 kilobases (kb) in all the four cell lines examined ( Figure 1A) , consistent with the expected size of VEGF mRNA (Tischer et al, 1991; Shima et al, 1995) . Scanning the intensities of the bands showed that the lowest level of VEGF mRNA was detected in the benign cell line PNT-2, this level was increased by 2.7-fold in the malignant cell line LNCap. Further increases of 4.3-fold and 8.5-fold were detected in the malignant metastasis-derived cell lines PC-3 and DU145 respectively. More accurate measurements of the VEGF mRNA level by slot-blotting detected similar differences between the benign and the malignant cell lines as those detected by Northern blotting. Relative to the lowest level expressed in the PNT-2 cell line, the level of VEGF mRNA in LNCap, PC-3 and DU145 cell lines was increased by 2.9 ± 0.5, 4.9 ± 0.7 and 10 ± 0.95-fold respectively ( Figure 1B) .
The levels of VEGF mRNA in the five Dunning R3327 rat carcinoma cell lines were measured using Northern blotting. As shown in Figure 2A , the expression of VEGF in these cell lines was elevated in direct correlation with the increase in their metastatic characteristics. The G-cell line, which has the lowest metastatic potential, expressed the lowest level of VEGF mRNA. The VEGF expression level was 2.9-fold higher in the weakly metastatic AT-2 cells than that in the G-cells. In the three highly metastatic cell lines, AT-3, MAT-Lu and AT-6.1, the expression of VEGF mRNA was 6-, 3.5-and 7.8-fold respectively higher than that expressed in the G-cells. The levels of VEGF mRNA in the benign rat Rama 37 cell line and its three malignant metastatic sublines were shown in Figure  2B . The lowest level was detected in the benign Rama 37 cells. Comparing with their parental benign Rama 37 cells, the amount of VEGF mRNA expressed in the RMP2c-Lu, RMP2c-H and RMP2b-Lu was increased by 2.5-, 4.5-and 3.4-fold respectively.
Detection of the VEGF isoforms in human benign and malignant cell lines
RT-PCR performed in the benign PNT-2 and the malignant DU145 cells ( Figure 3A) showed that two VEGF mRNA isoforms coding for VEGF 121 and VEGF 165 proteins, respectively, were transcribed in both the benign (lane 1) and the malignant (lane 2) cell lines. In addition to these two smaller transcripts, another band with a molecular size larger than the VEGF 165 transcript was detected in the malignant DU145 cells, but not in the benign PNT-2 cells ( Figure 3B ). Nucleotide sequence analysis revealed that the smallest band was VEGF 121, the middle-sized band was VEGF-165 and the largest band was VEGF 189.
VEGF protein secreted by human benign and malignant cell lines
At the protein level (Figure 4) , the difference in VEGF synthesis between the benign and the malignant cell lines was observed. The VEGF protein secreted by the benign PNT-2 cells (8 × 10 5 cells) was 1.3 ± 0.06 ng per 48 h. In contrast, the amounts of VEGF protein secreted in malignant LNCap cells and the malignant metastasis-derived PC-3 cells and DU145 cells were 2.7 ± 0.03 ng, 3.1 ± 0.09 ng and 7.9 ± 0.09 ng respectively, under the same culture condition.
Angiogenic activity of the VEGF protein produced by human benign and malignant cell lines
Conditioned media from a benign (PNT-2) and a malignant cell line (DU 145) cell line were collected for CAM assay, using rhVEGF 121 as the positive control. As shown in Figure 5A and 5D, the rhVEGF 121 induced a strong angiogenic response which was neutralized by a 50-fold excess of VEGF neutralizing antibody. The Total RNA (about 10 µg) from each cell line was subjected to electrophoresis in a 0.8% agarose gel. The separated RNAs were transferred onto a nylon membrane and hybridized with radioactively labelled rat VEGF cDNA probe. The washed membrane was exposed to a Kodak XAR-5 film for 5 days. The same membrane was re-hybridized with a radioactively labelled rat actin cDNA probe and visualized by exposure to Kodak film overnight. The relative hybridization was determined by measuring the intensities of the bands with densitometry scanning 
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response to conditioned medium from PNT-2 cells was weak ( Figure 5C ), but conditioned medium from DU145 cells showed a moderate angiogenic response ( Figure 5B ). The VEGF antibody completely neutralized the angiogenic effect of the conditioned medium from malignant DU145 cells ( Figure 5E ). However, there was no effect of the same antibody on the weakly angiogenesis induced by the conditioned medium from benign PNT-2 cells ( Figure 5F ). Quantitative analysis of angiogenesis induced by the above different additions was performed using the criteria described in Materials and Methods and shown in Figure 5G .
DISCUSSION
In this study, we have investigated the expression of VEGF in several benign and malignant cell lines from both human and rat cell models. Among the four human prostate cell lines, the weakly metastatic cell line LNCap expressed nearly three times the level of VEGF mRNA and twice the level of VEGF protein as that expressed in the benign PNT-2 cells. In the two malignant metastasis-derived cell lines, PC-3 and DU145, the expression of VEGF mRNA was fourfold and tenfold respectively higher than that expressed by the benign PNT-2 cells. These results suggest that the enhanced expression of the VEGF gene is associated with the malignant characteristics of human prostate cells, which is consistent with previous published works (Ferrer et al, 1997; Connolly and Rose 1998; Balbay et al, 1999; Melnyk et al, 1999) . A similar pattern of VEGF expression was also detected in the rat cell lines used. In the weakly metastatic cell line AT-2, the expression level of VEGF was nearly three times of that detected in the least malignant G-cells; whereas the expression of VEGF in the three highly metastatic cell lines AT-3, MAT-Lu and AT6.1 was 3.5-to 7.8-fold higher than that detected in the G-cells. These results not only show that the high level expression of VEGF was associated with the malignant phenotype of the prostatic epithelial cells, but that the elevated expression of VEGF was closely associated with the increasing metastatic characteristics of the malignant cells. As such, it is possible that VEGF may play an important role in the malignant dissemination of prostate cancer cells.
Higher levels of VEGF in serum or plasma have been evaluated as a predictor of outcome in patients with several malignant diseases (Dirix et al, 1996; Crew et al, 1997; Salven et al, 1997; Kraft et al, 1999; Molica et al, 1999) . Recently, it has also been suggested that the patients with metastatic prostate cancer have higher plasma VEGF levels than those with localized disease or healthy controls (Duque et al, 1999) . Over-expression of VEGF by malignant prostate carcinoma cells as shown by our investigation and other reports (Ferrer et al, 1997; Connolly and Rose 1998; Balbay et al, 1999; Melnyk et al, 1999 ) may contribute to the elevated serum or plasma VEGF levels. More studies are needed to confirm the predictive utility of the VEGF produced by malignant prostate cells themselves.
In this study, we also examined the isoform patterns of VEGF mRNA expressed by the cells with either benign or malignant characteristics. Five different isoforms of VEGF transcripts encoding polypeptides of 206, 189, 165, 145 and 121 amino acids have been reported to be expressed in human cells (Houck et al, 1991; Tischer et al, 1991; Poltorak et al, 1997) . Our results revealed that VEGF 121 and 165 were the predominant VEGF isoforms expressed by both benign and malignant human cell lines. Interestingly, an additional transcript representing VEGF 189 isoform was only detected in the malignant cells, but not in the benign cells. Recently, it was reported that colon cancer patients with liver metastasis showed significantly higher levels of VEGF 189 mRNA than those without liver metastasis. The expression of VEGF 189 isoform may be correlated with metastasis and a poorer prognosis in colon cancer (Tokunaga et al, 1998) . Combining this finding with our observation, the absence of VEGF isoform 189 in the benign PNT-2 cells may indicate that the increasing malignant characteristics of prostate carcinoma cells may not only be associated with the elevated level of VEGF, but also correlated with the expressed isoform patterns of VEGF gene. Further studies are needed to establish whether the expression of a particular VEGF isoform (e.g. VEGF 189) in malignant cells could be used clinically to predict the stage of prostate carcinoma or the outcome of patients with the disease.
Results from CAM assay demonstrated that the process of new blood vessel formation was markedly stimulated by conditioned medium from malignant DU145 cells, and this activity was completely abolished by a neutralizing anti-hVEGF antibody. Conversely, the weaker angiogenic activity induced by conditioned medium from the benign PNT-2 cells was not inhibited by the addition of the same neutralizing antibody. These results indicated that the moderate angiogenic activity of malignant cells was caused by the highly expressed VEGF protein whereas the low angiogenic activity observed in the conditioned medium from benign cells was caused by factors other than VEGF. This suggests that not only the level of VEGF was greatly increased in the malignant cells, but also the VEGF produced by the malignant cells played a greater, or pivotal role in stimulating angiogenesis than that produced by the benign cells. Thus, the elevated amount of angiogenically active VEGF derived from malignant cells may be responsible for the development of neovascularization in the microenvironment of secondary tumours. Since angiogenic activity can facilitate the process of cell metastasis (Liotta et al, 1991; Weidner, 1995) , it is possible that the metastatic capability of the malignant prostate cells may have been greatly facilitated by the high expression of biologically active VEGF, with its strong angiogenesis-promoting activity. To further test this hypothesis, we compared the expression levels of VEGF mRNA between the benign Rama 37 cell line (Dunnington et al, 1983) and its three metastatic variants, RMP2b-Lu, RMP2c-Lu and RMP2c-H. Northern blotting showed that the level of VEGF mRNA expressed in three metastatic cell lines were 2.6-to 4.8-fold higher than that expressed by their benign parental Rama 37 cells. This result indicated that both the capability of synthesizing high level VEGF and of disseminating to secondary sites, which are possessed by the DNA donor cells AT6.1, had been transformed into the DNA recipient cells Rama 37 through DNA transfection. Further studies determining how the metastasispromoting DNA from the donor cells up-regulates VEGF expression in the recipient cells could provide much needed insight into the molecular mechanism for the initiation and development of malignant progression in prostate and other malignant diseases.
Although we have generally found that the elevated expression of VEGF was closely associated with the increased metastatic potential of the cells, we observed a possible discrepancy between the malignant PC-3 and DU145 cell lines. It has been demonstrated that the metastatic potential of PC-3 is slightly higher than that of DU145 cells (Ke et al, unpublished observation) . However, in this work, the VEGF expression in DU145 was higher than that in PC-3, although both were much higher (ten-and nearly fourfold respectively) than that expressed by the benign PNT-2 cells. Since PC-3 was established from a rib metastasis (Kaighn et al, 1979) and DU145 was established from a brain metastasis (Stone et al, 1978) , the different growing microenvironments of the secondary tumours may have different requirements on the speed and degree of vascularization. More importantly, metastasis is the consequence of complicated molecular and genetic changes occurring in malignant cells. Whilst elevated expression of VEGF may be important in promoting and maintaining metastasis development, there may be more gene(s) involved in the initiation of malignant dissemination. Our recent work (accepted for publication by Cancer Research.) suggested that it is likely that the collective effect of several metastasis-related genes, rather than VEGF alone, determined the behaviour of the individual malignant cells. Although the over-expression of VEGF is important and seems to be essential for metastasis, the metastatic capability of the cells is not completely determined by VEGF alone. Thus, the discrepancy in VEGF expression observed between PC-3 and DU145 cells may reflect the differences in molecular complexities which caused the spread of the two separate clones to different secondary sites in the body.
In conclusion, we have now provided evidence to support a role for the angiogenically active VEGF derived from the malignant cells as a metastasis-associated gene in prostate cancer. Its relevance in the relative comparison between prostate cell lines of differing metastatic potential was further emphasized in the rat metastatic model of prostate cancer. VEGF ligand secreted by malignant prostate cells may be a key factor in inducing angiogenesis through paracrine mechanisms on the surface of endothelial cells and in so doing, greatly facilitate the process and development of metastasis. 
